Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 17, 2026 07:30 ET | Source: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell...
June 23, 2026 16:05 ET | Source: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

SAN DIEGO, June 23, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell...
June 08, 2026 06:30 ET | Source: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
May 28, 2026 08:00 ET | Source: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
May 19, 2026 16:05 ET | Source: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases

Late-breaking oral presentation to highlight AlloNK + rituximab clinical responses comparable to autologous CAR T-cell therapy in 31 patients with rheumatologic diseases, including 71% ACR50 response...
May 19, 2026 08:00 ET | Source: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development

Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development
May 08, 2026 06:52 ET | Source: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Artiva Biotherapeutics Announces Pricing of $300 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
May 08, 2026 06:31 ET | Source: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Artiva Biotherapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 08, 2026 06:30 ET | Source: Artiva Biotherapeutics, Inc.

Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial in Rheumatoid Arthritis in 2026

Artiva Announces Positive Initial Clinical Data with AlloNK® Across Multiple Autoimmune Diseases and FDA Alignment to Initiate Phase 3 Registrational Trial
April 08, 2026 08:00 ET | Source: Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

Artiva Biotherapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference